UNIPI Team Leader: Prof. Marta Mosca, Dipartimento di Medicina Clinica e Sperimentale

The identification of the molecular mechanisms that can positively or negatively influence a patient’s response to medical treatment is a key issue among health practitioners. A study promoted by 3TR, a consortium of university institutions, SMEs and leading pharmaceutical companies, will address this issue. This EU-funded project will apply bioinformatics and control methods to collect and analyse data from blood, tissues and other fluids during the entire treatment process. It will create a centralised data platform for better management and implement an inclusive molecular and clinical picture of patients experiencing similar diseases. The project intends to explain the role that our microbiome, genetics and regulatory genomics play during treatment.

3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions, SMEs, and 8 major pharmaceutical companies, teamed to study a fundamental issue in medicine: the mechanisms of response and non-response to therapies, the major aim of 3TR, both within single disease entities and across diseases, where molecular stratification may identify shared disease taxonomies. The molecular identification of groups of patients to whom a drug will benefit, will allow focusing on those who are drug orphan. Harmonization of data from existing academy or industry-sponsored studies will identify biomarkers to inform a new collection. Specimens of diseased tissues, blood, stools, and other fluids will be obtained in a de novo observational prospective trial with standard of care medication prior, during and after first or second line of treatment. Because the studies will be at different phases of progression, a carrousel model of work was designed for input and output of data to be continuously analysed, and interpreted, to inform those measurements to be undertaken and allow cross-validation of results. The 3TR team will elucidate the role of the microbiome, genetics and regulatory genomic features in disease progression.

The working aims of 3TR are: 1) establish a centralized data management platform; 2) perform comprehensive molecular and clinical characterisation of a prospective patient cohort; 3) establish integrated analysis of all data using advanced bioinformatics/statistical and modelling methods; 4) identify sets of predictive biomarkers of response/non-response to therapies; 5) improve the competitiveness of European industry and support development of novel solutions. 3TR will sustain beyond the project end the samples and its knowledge base. 3TR will challenge and revolutionize the conventional single-disease based approach with important implications in future disease treatment.

Coordinator
FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD, Spain

Participants

• THE UNIVERSITY OF MANCHESTER, United Kingdom
• CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL, Germany
• UNIVERSITY OF LEICESTER, United Kingdom
• EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH, Germany
• FUNDACIO CENTRE DE REGULACIO GENOMICA, Spain
• EUROPEAN RESPIRATORY SOCIETY, Switzerland
• FONDAZIONE IRCCS CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO, Italy
• ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM, Netherlands
• ACADEMISCH ZIEKENHUIS GRONINGEN, Netherlands
• ALACRIS THERANOSTICS GMBH, Germany
• ATRYS HEALTH, SA, Spain
• AZIENDA OSPEDALIERA DI PADOVA, Italy
• AZIENDA OSPEDALIERO-UNIVERSITARIA ANNA MEYER, Italy
• Universitair Ziekenhuis Gent, Belgium
• REGION HOVEDSTADEN, Denmark
• CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE NANCY, France
• UNIVERSITY OF GLASGOW, United Kingdom
• CHARITE - UNIVERSITAETSMEDIZIN BERLIN, Germany
• AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS, Spain
• CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER, Spain
• CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P., Spain
• Deutsches Rheuma-Forschungszentrum Berlin, Germany
• EUROPEAN FEDERATION OF ASTHMA &ALLERGY ASSOCIATIONS IDEELL FORENING, Belgium
• EUROPEAN LUNG FOUNDATION, United Kingdom
• GENOS DOO ZA VJESTACENJE I ANALIZU, Croatia
• IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE, United Kingdom
• INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, France
• INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES, Portugal
• KAROLINSKA INSTITUTET, Sweden
• LUPUS EUROPE, United Kingdom
• MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV, Germany
• MEDIZINISCHE HOCHSCHULE HANNOVER, Germany
• OREBRO UNIVERSITY, Sweden
• OWLSTONE MEDICAL LIMITED, United Kingdom
• PHILIPPS UNIVERSITAET MARBURG, Germany
• QUEEN MARY UNIVERSITY OF LONDON, United Kingdom
• SERVICIO ANDALUZ DE SALUD, Spain
• SERVICIO MADRILENO DE SALUD, Spain
• SIP SERVICE S.R.L., Italy
• SOCIETE DE PNEUMOLOGIE DE LANGUE FRANCAISE, France
• STICHTING VUMC, Netherlands
• TECHNISCHE UNIVERSITAET DRESDEN, Germany
• THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE, United Kingdom
• THE QUEEN'S UNIVERSITY OF BELFAST, United Kingdom
• UNIVERSITA DEGLI STUDI DI CATANIA, Italy
• UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO, Italy
• UNIVERSITA DEGLI STUDI DI CAGLIARI, Italy
• UNIVERSITA DEGLI STUDI DI GENOVA, Italy
• UNIVERSITA DI PISA, Italy
• UNIVERSITAT BASEL, Switzerland
• CLINIQUES UNIVERSITAIRES SAINT-LUC, Belgium
• UNIVERSITE DE BRETAGNE OCCIDENTALE, France
• UNIVERSITEIT HASSELT, Belgium
• UNIVERSITETET I BERGEN, Norway
• UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN, Ireland
• UNIVERSITY COLLEGE LONDON, United Kingdom
• KATHOLIEKE UNIVERSITEIT LEUVEN, Belgium
• UNIVERSITY OF SOUTHAMPTON, United Kingdom
• UNIVERSYTET MEDYCZNY W LODZI., Poland
• VIB VZW, Belgium
• SANOFI-AVENTIS DEUTSCHLAND GMBH, Germany
• JANSSEN PHARMACEUTICA NV, Belgium
• TAKEDA DEVELOPMENT CENTRE EUROPE LTD., United Kingdom
• ASTRAZENECA AB, Sweden
• GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD., United Kingdom
• NOVARTIS PHARMA AG, Switzerland
• PFIZER LIMITED, United Kingdom
• F. HOFFMANN-LA ROCHE AG, Switzerland

Start date 1 September 2019
End date 31 August 2026
Project cost € € 80 803 177,75
Project funding € 40 273 191,50
Unipi quota € 292 500
Call title H2020-JTI-IMI2-2018-14-two-stage
Unipi role Participant
Project website https://3tr-imi.eu/